What diseases and conditions are specifically included in the indications of Besudil/Yilaike?

Belumosudil mesylate tablets (Belumosudil) are mainly suitable for the treatment of chronic graft-versus-host disease (cGvHD). It is an innovative drug developed for patients who are long-term refractory or have failed to achieve satisfactory results from previous treatments. cGvHD is a common immune-related complication after transplantation. The patient's skin, liver, mucosa and internal organs may suffer from fibrosis and inflammatory damage. Traditional immunosuppressive drugs often have unstable efficacy or poor tolerance. By regulating the ROCK signaling pathway, besudil can effectively interfere with immune cell activity, inhibit abnormal fibrosis, and thereby alleviate the symptoms of multi-organ involvement.

In clinical application, besudil is not only used in patients with obvious skin and mucosal damage, but also in patients with liver function involvement or progression of pulmonary fibrosiscGvHD. The drug can suppress abnormal immune responses while minimizing the impact on the body's normal immune defense function, allowing patients to balance efficacy and safety during long-term treatment. In addition, the oral administration method of besudil is more convenient, providing a convenient treatment option for patients who are unable to take long-term intravenous administration or are intolerant to traditional immunosuppressive drugs.

In addition tocGvHD, besudil is also focused on potential applications in other fibrosis-related diseases during the research and development stage, such as systemic sclerosis or organ transplantation-related fibrosis. However, the current domestically approved indications are limited to chronic graft-versus-host disease. For patients, understanding the indications and scope of use of drugs can help them scientifically choose treatment options under the guidance of doctors while avoiding unnecessary drug risks.

To sum up, the clinical value of besudil is mainly reflected in its immunomodulatory and anti-fibrotic effects on patients with long-term refractory cGvHD, providing patients with innovative, convenient and targeted treatment options.

Reference: https://www.drugs.com/pro/rezurock.html